Kezar licenses zetomipzomib to Everest for up to $132.5M in Greater China & SE Asia

Kezar Life Sciences, Inc.

Kezar receives $7.0M upfront; eligible for up to $132.5M in development, regulatory & commercial milestones.
Everest gets exclusive rights to develop and commercialize zetomipzomib for non-oncology uses in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines.
Parties will collaborate on PALIZADE Phase 2b lupus nephritis trial; Everest contributes local expertise and covers costs in licensed territories.
Tiered royalties from single-digit to low-teens on net sales; Kezar supplies drug with Everest option to manufacture after PALIZADE.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Kezar Life Sciences, Inc. entered into Collaboration and License Agreement with Everest Medicines II (HK) Limited valued at initial upfront payment of $7.0 million; potential milestone payments of up to $125.5 million; tiere (effective 2023-09-20).

Action: entry
Agreement: license
Counterparty: Everest Medicines II (HK) Limited
Value: initial upfront payment of $7.0 million; potential milestone payments of up to $125.5 million; tiere
Effective: 2023-09-20

Exact text from the filing

On September 20, 2023, Kezar Life Sciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “License Agreement”) with Everest Medicines II (HK) Limited (“Everest”) pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company’s proprietary compound, zetomipzomib (collectively, the “Products”), in the licensed field in the greater China region (mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the “Territory”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-049044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.